| EBITDA Margin guidance | 22.5% → 23.0% Raised by 0.5 percentage points |
|---|
| Revenue growth | 51% YoY growth; USD revenue up 32% YoY to $55 million. |
|---|---|
| Margins | Gross margin up 140 bps sequentially to 67.7%; Operating EBITDA at 24.2%. |
| Demand visibility | Strong traction for revenue; very strong visibility in coming quarters. |
| Management confidence | High; citing strong visibility and broad-based growth across portfolio. |
Growth
Revenue grew 51% YoY; EBITDA rose 65% to ₹131 Cr; Operating EBITDA margin expanded to 24.2%.
Outlook
EBITDA guidance for FY27 raised to 23% (from 22-23%). Pithampur and NJ facilities to ramp up by CY2027.
Risks
Geopolitical conditions increasing input and freight costs; new facility pre-revenue costs; ESOP costs impacting near-term margins.
Last quarter's promises, checked
Delivered
- EBITDA range 22-23% → delivered 24.2% (= BEAT)
- R&D productivity 5.7x → delivered 5.9x (= BEAT)
- Pithampur ramp-up Q1 CY27 → on track/pre-revenue (= BEAT)
Partly delivered
- Gross margins to improve via internal mfg → reliance on outsourcing remains high (= PARTIAL)
Investor Presentation filed with BSE, NSE: RUBICON. Summary written with AI assistance from the document.
Rubicon Research Ltd: key numbers
- Share price
- ₹1,676.30
- Market cap
- ₹27,748 Cr
- Revenue (annual)
- ₹1,754 Cr
- Net profit (annual)
- ₹246.7 Cr
- P/E (TTM)
- 96.3×Sector 50.4×
- Promoter holding
- 59.76%-0.10% QoQ
- FII holding
- 7.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rubicon Research Ltd
All →Rubicon Research Capital Structure Change
Employee Girish Subramaniam Iyer sold 6,796 shares in the open market across four transactions for a total consideration of ₹1.23 Crore.
- Value
- ₹1.23 Cr
Rubicon Research Other Announcement
Employee Vinayak Sawant sold 1,100 shares of Rubicon Research Ltd worth ₹0.20 Crore. This disclosure is a routine regulatory filing under PIT regulations.
- Value
- ₹0.20 Cr
Rubicon Research Earnings Call Transcript: Key Takeaways
Rubicon Research delivers stellar Q1FY27 results with a 51% revenue jump and 100%+ PAT growth, largely fueled by strong US specialty sales and successful inorganic integration.
Rubicon Research Investor Presentation: Key Takeaways
Rubicon Research reported stellar Q1FY27 results with 51.6% YoY revenue growth. Management revised Operating EBITDA margin guidance upwards to at least 23% for FY27.
Rubicon Research Q1 FY27 Results: Net Profit ₹84.8 Cr, Up 95.8% YoY
Rubicon Research Ltd reported revenue from operations of ₹534.3 Cr (+51.6% YoY) and net profit of ₹84.8 Cr (+95.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹84.8 Cr · +95.8% YoY
Rubicon Research Earnings Call: Key Takeaways
Rubicon Research reports robust Q4 FY26 results with 44% revenue growth and 112% PAT growth. Strategy shifts toward direct Indian market presence via Arinna Lifesciences acquisition.